Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Inv. presentation
Quarterly results
Credit agrmnt [a]
Appointed director
Athenex, Inc. (ATNX) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/07/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 7, 2019 ATHENEX, INC. Delaware 001-38112 43-1985966 1001 Main Street, Suite 600, Buffalo, New York 14203 Registrant's telephone number, including area code: 427-2950 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement commu...",
"Athenex, Inc. Announces Third Quarter 2019 Financial Results Oral presentation of Phase III Oral Paclitaxel data at the San Antonio Breast Cancer Symposium NDA submissions for Oral Paclitaxel and tirbanibulin ointment are on track $19.2 million of product sales in Q3 2019, a 45% year-over-year increase Raising full year 2019 guidance to 35% to 40% year-over-year growth Conference call and live audio webcast at 8:00 a.m. Eastern Time today BUFFALO, N.Y., November 7, 2019 — Athenex, Inc. , a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced its financial results and business highlights for the third quarter of 2019. “We continue to make strong progress across th..."
08/07/2019 8-K Quarterly results
Docs: "Athenex, Inc. Announces Second Quarter 2019 Financial Results, Positive Phase III Results on Oral Paclitaxel plus Encequidar and Increased Product Sales Guidance",
"Athenex Announces Oral Paclitaxel and Encequidar had a Significantly Higher Response Rate Over IV Paclitaxel in a Phase III Pivotal Study in Metastatic Breast Cancer"
05/09/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 9, 2019 ATHENEX, INC. Delaware 001-38112 43-1985966 1001 Main Street, Suite 600, Buffalo, New York 14203 Registrant's telephone number, including area code: 427-2950 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communicat...",
"Athenex, Inc. Announces First Quarter 2019 Financial Results and Provides Corporate Update"
11/14/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 14, 2018 ATHENEX, INC. Delaware 001-38112 43-1985966 1001 Main Street, Suite 600, Buffalo, New York 14203 Registrant's telephone number, including area code: 427-2950 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement comm...",
"Athenex, Inc. Announces Third Quarter 2018 Financial Results and Provides Corporate Update"
08/14/2018 8-K Quarterly results
Docs: "FORM 8-K",
"Athenex, Inc. Announces Second Quarter 2018 Results and Provides Corporate Update"
05/14/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 14, 2018 ATHENEX, INC. Delaware 001-38112 43-1985966 1001 Main Street, Suite 600, Buffalo, New York 14203 Registrant's telephone number, including area code: 427-2950 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communica...",
"First Quarter 2018 and Recent Business Highlights:"
03/26/2018 8-K Quarterly results
Docs: "Athenex, Inc. Announces Fourth Quarter and Full-Year 2017 Results Fourth Quarter 2017 and Recent Business Highlights:"
11/09/2017 8-K Quarterly results
Docs: "Athenex, Inc. Announces Third Quarter 2017 Results"
08/14/2017 8-K Quarterly results
Docs: "Athenex, Inc. Announces Second Quarter 2017 Results"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy